Similar articles

• [TKI therapy for CML].

  Ohnishi K. Ohnishi K. Rinsho Ketsueki. 2011 Jul;52(7):452-9. Rinsho Ketsueki. 2011. PMID: 21821976 Review. Japanese. No abstract available.
• Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.

  Okabe S, Tauchi T, Ishii Y, Akahane D, Nunoda K, Honda S, Takaku T, Ohyashiki K. Okabe S, et al. Int J Hematol. 2007 Feb;85(2):173-4. doi: 10.1532/IJH97.06187. Int J Hematol. 2007. PMID: 17321998 Review. No abstract available.
• Effects of lower dose of imatinib to CML patients.

  Horikoshi A, Takei K, Sawada S. Horikoshi A, et al. Leuk Res. 2003 Dec;27(12):1167. doi: 10.1016/s0145-2126(03)00101-2. Leuk Res. 2003. PMID: 12921957 No abstract available.
• [Experimental advance of targeted medicines for chronic myeloid leukemia--review].

  Yang DG. Yang DG. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Feb;15(1):211-4. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007. PMID: 17490557 Review. Chinese.
• Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).

  Chrobák L, Voglová J. Chrobák L, et al. Acta Medica (Hradec Kralove). 2003;46(3):85-9. Acta Medica (Hradec Kralove). 2003. PMID: 14677715 Review.